EGFR and neoplasm: Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI), has been shown to be effective in NSCLC tumors exhibiting allele frequencies of EGFR-activating and/or EGFR-resistance mutations in plasma circulating tumor DNA (ctDNA), which are independently associated with poorer survival outcomes [15].